iRobot Corporation (IRBT)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRobot Corporation (“iRobot” or “the Company”) (NASDAQ: IRBT). Investors who purchased iRobot securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether iRobot has violated federal securities laws.

Investigation Details:

On August 5, 2022, iRobot and Amazon.com, Inc. (“Amazon”) announced entry into a definitive merger agreement, pursuant to which Amazon would “acquire iRobot for $61 per share in an all-cash transaction valued at approximately $1.7 billion, including iRobot’s net debt” (the “Merger Agreement”). Then, on January 29, 2024, Amazon and iRobot announced entry “into a mutual agreement” to terminate the previously announced Merger Agreement, after struggling to gain approval from regulatory authorities in the U.S. and Europe. Concurrently, iRobot announced the resignation of its Chief Executive Officer and Chairman, as well as plans to cut approximately 31% of its workforce. On this news, Robot’s stock price fell sharply on January 29, 2024.

What’s Next?

If you are aware of any facts relating to this investigation or purchased iRobot securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

332-239-2660 | [email protected]